Drug Type Small molecule drug |
Synonyms WZB117 |
Target |
Action inhibitors, antagonists |
Mechanism GLUT1 inhibitors(Glucose transporter 1 inhibitors), GRIN3A antagonists(glutamate ionotropic receptor NMDA type subunit 3A antagonists), GluN1 inhibitors(glutamate ionotropic receptor NMDA type subunit 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC20H13FO6 |
InChIKeyFRSWCCBXIHFKKY-UHFFFAOYSA-N |
CAS Registry1223397-11-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Nervous System Diseases | Preclinical | China | 09 Jun 2022 | |
Neoplasms | Preclinical | United States | 08 Aug 2012 |